A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer

Cheng Jian-hua; Liu Wei-sheng; Li Zhi-ming; Wang Zhi-guang

doi:10.1007/s11655-007-0269-4

Your Location：

Home >

Browse articles >

A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer

Updated：2021-08-27

- A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer
- Chinese Journal of Integrative Medicine Vol. 13, Issue 4, Pages: 269-274(2007)
- Affiliations：
  
  Guangdong Provincial Traditional Chinese Medicine Hospital,Guangzhou,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-007-0269-4
  CLC：
- Published：2007，
Scan for full text
Cheng, Jh., Liu, Ws., Li, Zm. et al. A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer., Chin. J. Integr. Med. 13, 269–274 (2007). https://doi.org/10.1007/s11655-007-0269-4

Cheng Jian-hua, Liu Wei-sheng, Li Zhi-ming, et al. A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 13(4):269-274(2007)
Cheng, Jh., Liu, Ws., Li, Zm. et al. A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer., Chin. J. Integr. Med. 13, 269–274 (2007). https://doi.org/10.1007/s11655-007-0269-4 DOI：

Cheng Jian-hua, Liu Wei-sheng, Li Zhi-ming, et al. A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 13(4):269-274(2007) DOI： 10.1007/s11655-007-0269-4.

摘要

To assess the clinical efficacy of global traditional Chinese medicine (TCM) therapy in treating senile advanced non-small cell lung cancer (NSCLC)

with the aim of seeking a standardized

rational and economical way to treat advanced NSCLC in old patients. A retrospective analysis and comparison was carried out in 86 patients with senile advanced NSCLC

44 treated by global TCM (TCM group) and 42 by chemotherapy (control group) through dynamical observation on related indexes including tumor size

quality of life and the survival time

as well as on the fee for medical service at various time points in the course of the treatment. The changes of tumor size

score of clinical main symptoms and behavior condition (by ZPS scoring)

as well as survival rates in the two groups at corresponding time points

were not different significantly (P>0.05). The mean survival time in the TCM group was 13.20±1.52 months and that in the chemotherapy group was 13.45±1.94 months

showing insignificant difference between them. However

the median survival time in the TCM group (12 months) was actually longer than that in the chemotherapy group (9 months

P<0.05). The mean daily expense and the mean expense (RMB yuan) for each patient in the TCM group were significantly lower than that in the control group

which was 180.73±93.21 vs 825.84±329.63 for the mean daily expense and 34 077.21±14 638.04 vs 58 516.59±45 429.76 for the mean expense for each patient (both P<0.01). Treatment of senile advanced NSCLC with TCM alone has its apparent superiority in stabilizing tumor focus

improving clinical symptoms

elevating quality of life and prolonging the survival time. TCM is also less expensive

making it a good alternative therapeutic approach for this specific group of people.

Abstract

To assess the clinical efficacy of global traditional Chinese medicine (TCM) therapy in treating senile advanced non-small cell lung cancer (NSCLC)

with the aim of seeking a standardized

rational and economical way to treat advanced NSCLC in old patients. A retrospective analysis and comparison was carried out in 86 patients with senile advanced NSCLC

44 treated by global TCM (TCM group) and 42 by chemotherapy (control group) through dynamical observation on related indexes including tumor size

quality of life and the survival time

as well as on the fee for medical service at various time points in the course of the treatment. The changes of tumor size

score of clinical main symptoms and behavior condition (by ZPS scoring)

as well as survival rates in the two groups at corresponding time points

were not different significantly (P>0.05). The mean survival time in the TCM group was 13.20±1.52 months and that in the chemotherapy group was 13.45±1.94 months

showing insignificant difference between them. However

the median survival time in the TCM group (12 months) was actually longer than that in the chemotherapy group (9 months

P<0.05). The mean daily expense and the mean expense (RMB yuan) for each patient in the TCM group were significantly lower than that in the control group

improving clinical symptoms

elevating quality of life and prolonging the survival time. TCM is also less expensive

making it a good alternative therapeutic approach for this specific group of people.

关键词

Traditional Chinese Medicine Therapyglobalsenileadvanced non-small cell lung cancer

Keywords

Traditional Chinese Medicine Therapyglobalsenileadvanced non-small cell lung cancer

references

Chinese Medicine Association. Guide of clinical diagnosis and treament. Volume of Oncology. Beijing: People’s Medical Publishing House, 2005:106–107, 129–130.

Chu DT, ed. Evaluation on contemporary oncology Internal therapy regimen. Beijing: Peking Medical University Press, 1998:153–165.

Sun Y, ed. Oncology of internal medicine. Beijing: People’ s Medical Publishing House, 2000:996–997.

Chen KJ, ed. Lung Cancer. Beijing: China Medico-Pharmaceutical Sciences and Technology Publishing House, 2000:3–4.

Xu ZY, Yang YF, eds. Integrated traditional Chinese and Western therapy of lung cancer. People’s Medical Publishing House, 2002:7–8.

Gu YQ. Epidemiology and therapy characteristics of senile oncology. Geriatr Health Care (Chin) 2002;8(2):74–76.

Wu YL, ed. Theory and practice of multi-subject combination therapy on lung cancer. Beijing: People’ s Medical Publishing House, 2000:7–8.

Ricci S, Antonuzzo A, Galli L, et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. Lung Cancer 2000;27:75–80.

Hainsworth JD, Burris HA 3rd, Litchy S, et al. Weekly docetaxel in the treatment of elderly pantients with advanced non-small cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000;89:328–330.

The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of winorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66–72.

Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer 1998;34:1710–1714.

Medical Politics Office, P. R. China. Standardization of diagnosis and treatment of malignant tumor-Primary bronchogenic carcinoma of lung. 2nd ed. Beijing: People’s Medical Publishing House, 1991:3–4.

Luo J, Chu DT. Evaluation of the role of quality of life in treatment of malignant tumor with traditional Chinese medicine. Chin J Oncol (Chin) 2002;24(4):41–42.

FULL TEXT LINK

More>

Views

342

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine

A multi-center randomized double-blind placebo-controlled trial of Xiongshao Capsule (芎芍胶囊) in preventing restenosis after percutaneous coronary intervention: A subgroup analysis of senile patients

Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer

Effect of Tiaozhi Yanggan Decoction (调脂养肝汤) in treating patients with non-alcoholic fatty liver

A survey on treatment of dry eye by traditional chinese medicine and integrative Chinese and Western medicine

Related Author

No data

Related Institution

Department of Radiology, Chinese People’s Liberation Army General Hospital

Department of Traditional Chinese Medicine, Chinese People’s Liberation Army General Hospital

Xiyuan Hospital, China Academy of Chinese Medical Sciences

National Integrative Medicine Center for Cardiovascular Diseases, China-Japan Friendship Hospital

Beijing University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰